Victoria Socha

DocwireNews

Patients with renal cell carcinoma (RCC) or urothelial carcinoma (UC) with clinically significant autoimmune disorders (AD) are commonly excluded from trials of <a href="https://www.docwirenews.com/latest-nephrology-news/circulating-tumor-dna-in-metastatic-ccrcc/">immune checkpoint inhibitors</a> (CPI) due to potential AD exacerbation. As a result, there are few available data on the safety and clinical mechanism of CPI in patients with AD.In a retrospective data analysis, researchers, led by Nieves Martinez Chanza, MD, of the <a href="https://www.bordet.be/en/homepage">Jules Bordet Institute, Brussels, Belgium</a>,&nbsp; collected data from nine centers on patients with RCC and UC with AD who were treated with CPI. Common Terminology Criteria for Adverse Events (version 5.0) (CTCAEv5) criteria were used to assess adverse events (AEs); Response Evaluation Criteria in Solid Tumors (RECIST) principles were used to assess objective response rate (ORR); and Kaplan Meier models were used to estimate overall survival. Results were reported during a poster session at the ASCO 2019 Annual Meeting in a poster titled Retrospective Analysis of the Safety and Efficacy of immune checkpoint inhibitors (CPI) among Patients (pts) with Pre-existing Autoimmune Disorders (AD) and Renal Cell Carcinoma or Urothelial Carcinoma (UC).A total of 103 patients (57 with RCC and 46 with UC) exhibited a broad spectrum of AD, including psoriasis (22%), thyroiditis (20%), rheumatoid arthritis (13%), polymyalgia rheumatica (8%), inflammatory bowel disease (6%), multiple sclerosis (3%), and lupus (3%). Most received CPI as first- or second-line (77% of RCC patients; 93% of UC patients) and anti-PD/L1 monotherapy (65% of RCC patients; 98% of UC patients).At start of CPI therapy, 36 patients had clinically active AD (all grade 1-2) and four required systemic immunosuppression. Thirty-eight patients had AD exacerbations, including arthritis (12% RCC; 24% UC), and rash (11% RCC; 9% UC).Thirty-seven patients experienced new onset immune-related AEs, including colitis (12% RCC; 4% UC), rash (11% RCC; 9% UC), hypothyroid (7% RCC; 7% UC), and nephritis (7% UC).Median follow-up was 12.5 months (range, 1-52 months) for RCC and 14.5 months (range, 1-53 months) for UC. Median time on CPI was 6 months (range, 1-36 months) for RCC and 4 months (range, 0.5-40 months) for UC. At time of data cutoff, 39 patients with RCC and 36 with US had discontinued CPI: 16% for toxicity. ORR was 31% for patients with RCC and 35% for patients with UC. The 1-year overall survival rate was 74% (95% confidence interval [CI], 58%-84%) for patients with RCC and 60% (95% CI, 43%-74%) for patients with UC.&ldquo;AD exacerbations or new acquired immune related AEs occurred in 37% and 36%, respectively, and were generally manageable. Only a minority required CPI cessation due to toxicity,&rdquo; the researchers said.Source: Chanza NM, Xie W, Issa M, et al. Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC). Abstract of poster 4571 presented at the American Society of Clinical Oncology 2019 Annual Meeting, June 3, 2019, Chicago, Illinois.

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

Autoimmune Disorders and CPI in Patients with RCC

ASCO 2019

Patients with renal cell carcinoma (RCC) or urothelial carcinoma (UC) with clinically significant autoimmune disorders (AD) are commonly excluded from trials of immune ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe